These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 22829086)

  • 1. [Infections and fingolimod].
    Cervera C
    Rev Neurol; 2012 Aug; 55(4):227-37. PubMed ID: 22829086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.
    Scott LJ
    CNS Drugs; 2011 Aug; 25(8):673-98. PubMed ID: 21790210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A; Castilló J; Montalban X
    Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Calabresi PA; Radue EW; Goodin D; Jeffery D; Rammohan KW; Reder AT; Vollmer T; Agius MA; Kappos L; Stites T; Li B; Cappiello L; von Rosenstiel P; Lublin FD
    Lancet Neurol; 2014 Jun; 13(6):545-56. PubMed ID: 24685276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral fingolimod for the treatment of relapsing-remitting multiple sclerosis.
    Vasiliou S
    Drugs Today (Barc); 2010 May; 46(5):315-25. PubMed ID: 20517533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.
    Tanaka M; Park K; Tanaka K
    Mult Scler; 2013 Aug; 19(9):1244-5. PubMed ID: 23322501
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B; Ross AP; Tobias K
    Int J Clin Pract; 2011 Aug; 65(8):887-95. PubMed ID: 21679286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
    Fazekas F; Berger T; Fabjan TH; Ledinek AH; Jakab G; Komoly S; Kraus J; Kurča E; Kyriakides T; Lisý L; Milanov I; Panayiotou P; Jazbec SS; Taláb R; Traykov L; Turčáni P; Vass K; Vella N; Havrdová E
    Wien Med Wochenschr; 2012 Aug; 162(15-16):354-66. PubMed ID: 22895849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia.
    La Mantia L; Prone V; Marazzi MR; Erminio C; Protti A
    Neurol Sci; 2014 Sep; 35(9):1485-6. PubMed ID: 24756193
    [No Abstract]   [Full Text] [Related]  

  • 12. Central effects of fingolimod.
    Cruz VT; Fonseca J
    Rev Neurol; 2014 Aug; 59(3):121-8. PubMed ID: 25030072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
    Cohen JA; Barkhof F; Comi G; Hartung HP; Khatri BO; Montalban X; Pelletier J; Capra R; Gallo P; Izquierdo G; Tiel-Wilck K; de Vera A; Jin J; Stites T; Wu S; Aradhye S; Kappos L;
    N Engl J Med; 2010 Feb; 362(5):402-15. PubMed ID: 20089954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
    Massberg S; von Andrian UH
    N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
    [No Abstract]   [Full Text] [Related]  

  • 15. Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
    Pfender N; Jelcic I; Linnebank M; Schwarz U; Martin R
    Neurology; 2015 Jun; 84(23):2377-8. PubMed ID: 25957334
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and efficacy of reduced fingolimod dosage treatment.
    Yamout BI; Zeineddine MM; Sawaya RA; Khoury SJ
    J Neuroimmunol; 2015 Aug; 285():13-5. PubMed ID: 26198913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis.
    Chun J; Hartung HP
    Clin Neuropharmacol; 2010; 33(2):91-101. PubMed ID: 20061941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral fingolimod (FTY720) for relapsing multiple sclerosis.
    Kappos L; Antel J; Comi G; Montalban X; O'Connor P; Polman CH; Haas T; Korn AA; Karlsson G; Radue EW;
    N Engl J Med; 2006 Sep; 355(11):1124-40. PubMed ID: 16971719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
    Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
    Cohen JA; Chun J
    Ann Neurol; 2011 May; 69(5):759-77. PubMed ID: 21520239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.